Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Norketotifen in Healthy Subjects
NCT03712163Phase 1Completed
- Sponsor
- Emergo Therapeutics
- Start
- Oct 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of norketotifen in influenza and influenza-like illness (ILI) (5 arms), sponsored by Emergo Therapeutics. Primary endpoints: Number of subjects with adverse events following single doses at Day 4 and Number of subjects with adverse events following multiple doses at Day 7. Started Oct 2018; status: completed.
02
Drugs
norketotifen
03
Conditions
influenzainfluenza-like illness (ILI)
Beyond the preview
Go deeper on NCT03712163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03712163.